DNTH

Insider trade Sale by Paula Soteropoulos

22d ago

News Dianthus Therapeutics GAAP EPS of -$0.85 beats by $0.23, revenue of $0.46M beats by $0.1M

28d ago

SEC filing DNTH Reports $719M Gross Proceeds, $1.2B Cash, Orphan Drug Designation for Claseprubart in Myasthenia Gravis, Phase 3 gMG Trial On Track for Mid-2026 Initiation, Top-Line Results Expected 2H’28, Phase 2 MoMeNtum Ongoing, Phase 1 DNTH212 Data Anticipated 2H’26, Building Rheumatolo

28d ago

Insider trade Sale by Ryan Savitz (EVP, CFO & CBO)

53d ago

Insider trade Sale by Edward Carr (CHIEF ACCOUNTING OFFICER)

80d ago

Insider trade Sale by Marino Garcia (CEO AND PRESIDENT)

80d ago

Insider trade Sale by Simrat Randhawa (EVP, Head of R&D)

80d ago

News Dianthus Therapeutics prices upsized $625M public offering at $81/share

83d ago

SEC filing DNTH Reports $514.4M Cash, $0.00 EPS, GO Decision in CAPTIVATE CIDP Trial, Phase 3 gMG Initiation 2026, MoMeNtum MMN 2H26 Data, DNTH212 2H26 Update

85d ago

News Lithium Royalty Corp. Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order – Company Announcement

126d ago

Short interest Short Interest

140d ago

News Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

153d ago

Scanner Unusual volume (z=10.7)

160d ago

Scanner Unusual volume (z=11.1)

162d ago

Scanner Unusual volume (z=11.1)

163d ago

Scanner Unusual volume (z=11.1)

164d ago